 |
|
Drug- and Placebo-Treated Neurotic OutpatientsPretreatment Levels of Manifest Anxiety, Clinical Improvement, and Side Reactions
Karl Rickels, MD;
Robert W. Downing, PhD
Arch Gen Psychiatry. 1967;16(3):369-372.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
CLINICAL experience in the treatment of neurotic outpatients with tranquilizing drugs, as well as previous research,1-4 has led us to expect that the role played by personality factors in response to treatment may be quite different in drug-treated and in placebo-treated patients. It is our belief that both similarities and differences, which emerge when the role of personality factors in the responses of drug- and placebo-treated patients are compared, may throw light upon the manner in which patient variables affect drug treatment, thereby having important methodological implications for psychopharmacological research. In this paper we shall consider the relationship of patient pretreatment anxiety level, derived from the Taylor Manifest Anxiety Scale (TMAS),5 to patient report of side reactions and to a global rating of clinical improvement after a four-week course of treatment with either a minor tranquilizer or placebo.
In general,
. . . [Full Text PDF of this Article]
Author Affiliations
Philadelphia
From the departments of psychiatry, Philadelphia General Hospital and the University of Pennsylvania, Philadelphia.
Footnotes
Submitted for publication Aug 2, 1966.
Reprint requests to 203 Piersol Bldg, University Hospital, 3400 Spruce St, Philadelphia 19104 (Dr. Rickels).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
